Abstract: Objective: To study the expression of vascular endothelial growth factor (VEGF), endocrine gland-derived VEGF (EG-VEGF/PK1) and its receptors (PKR1 and PKR2) in eutopic and ectopic endometrial tissues. Design: A case control study. Setting: University reproduction unit.
INTRODUCTION
Endometriosis refers to the presence of endometrial tissues outside the uterine cavity. It occurs spontaneously in humans and non-human primates including baboons and macaques but is rare in other animal species (1) . Endometriosis is a common gynaecological disease affecting 6-10% women of reproductive age. Affected women have higher risk than the general female population in developing cancers, autoimmune and atopic disorders (2) . Its etiology and pathophysiology are still unclear. Endometrial tissues in the uterus (eutopic) and outside the uterine cavity (ectopic) respond to the cyclical changes of steroid hormones. However, the proportions of estrogen and progesterone receptors, as well as the histology are different between paired eutopic and ectopic endometrial samples (3) (4) (5) .
Angiogenesis is important in the development of endometriosis (6) (7) (8) .
Angiostatic treatment reduces the number of endometriotic lesions at implantation in the chick chorioallantoic membrane model (9) and after implantation in the nude mice model (10) . Various growth factors including vascular endothelial growth factor (VEGF) have been found to be associated with angiogenesis in endometriosis (6, 10, 11) .
Endocrine gland-derived vascular endothelial growth factor (EG-VEGF) belongs to the prokineticin family. It is also known as prokineticin 1 (PK1), and shares about 44% amino acid homology with prokineticin 2 (PK2) or Bv8 (12). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 F & S 5688 revision 7 (12, 13) . Although EG-VEGF is structurally distinct from VEGF, they induce similar angiogenic response in the ovary (15, 16) .
EG-VEGF acts via G-protein coupled receptors, PKR1 and PKR2 (17, 18) , and induces mitogen-activated protein kinase (MAPK) and Akt serine/threonine kinase phosphorylation in bovine adrenal capillary endothelial cells (17) , HEK293 (18) , adrenal cortex-derived endothelial (ACE) cells (19) , neuroblastoma cell line (SK-N-SH, 20) and human uterine microvascular endothelial cell (Ut-HVEC-Myo, 21 ). Human PKR1 and PKR2 shared 85% amino acid identity and are most divergent in their N-terminal sequences (18) .
Prokineticins and their receptors are likely to be involved in reproduction as they are expressed in male reproductive tissues including testis and prostate (22, 23) , and in female reproductive tissues such as ovary, uterus and various tissues during pregnancy (16, 24, 25) . EG-VEGF has also been implicated in the pathology of the reproductive tract (26) , including Leydig cell neoplasms (27) , prostate cancer (23), ovarian carcinoma (15) and polycystic ovarian syndrome (16) . Whether EG-VEGF is involved in endometriosis is unclear. During early pregnancy and in hypoxic conditions, hypoxia-inducible factor-1 (HIF-1α) binds to the promoter of EG-VEGF and PKR1 leading to up-regulation of these genes in the placenta (13, 25, 26) .
Interestingly, transient hypoxia also up-regulates HIF-1α and induces the expression of VEGF in endometrium (28) and transplanted endometriosis-like lesions (29) . In the mice model, suppression of HIF-1α decreases VEGF production and inhibits growth of the transplanted endometriosis-like lesions (29) . 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65   F & S 5688 revision   8 the peri-implantation endometrium after gonadotropin-stimulation and hormone replacement therapy suggests that the production of EG-VEGF is hormone dependent (30, 31) . Despite all these observations, the function of EG-VEGF in the uterus remains unknown.
In view of the importance of angiogenesis in the development and progression of endometriosis, the involvement of multiple factors in the regulation of angiogenesis and HIF-1α target genes in endometriosis, and the potential angiogenic role of EG-VEGF in endometrium, we hypothesized that aberrant expression of EG-VEGF could be associated with the pathogenesis of endometriosis. In this study, we used laser micro-dissection technique to isolate paired human eutopic and ectopic endometriotic biopsies for real-time PCR analysis on VEGF, EG-VEGF and PKR1
and PKR2 mRNA expression. The increased expression of EG-VEGF mRNA and protein in ectopic endometriotic tissues suggests this molecule is associated with the progression of the disease. 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 
Immunohistochemical Staining
Antibody against human EG-VEGF was obtained from R&D Systems 
Statistical Analysis
Data were analyzed using the SigmaPlot software package (Jandel Scientific, San Rafael, CA 
RESULTS

Expression of EG-VEGF, PKR1 and PKR2 in Normal and Eutopic
Endometrial Tissues
To determine if there were differences in the mRNA expression levels of EG-VEGF, PKR1 and PKR2 between eutopic endometrium from normal women (NE, n=33) and eutopic endometrium of diseased women with endometriosis (DE, n=15), tissue samples were divided into 4 groups: normal proliferative endometrium (n = 14), normal secretory endometrium (n = 19); eutopic proliferative endometrium with endometriosis (n = 9) and eutopic secretory endometrium with endometriosis (n = 6).
The relative expression of the three transcripts was normalized to 18S and calculated by the equation: 2 -Ct using the proliferative phase normal endometrium (NE) as calibrator. It was found that normal endometrium (NE) at secretory phase expressed significantly (p<0.05) higher EG-VEGF (50-fold) but lower PKR1 (6-fold) mRNA when compared with that of the normal proliferative phase samples (Table 1 , Figure   1A and B). PKR2 transcript was detected in the normal proliferative endometrium but not in the normal secretory endometrium. (Table 1 and Figure 1C ). The expression of PKR2 in the eutopic proliferative endometrium from patients with endometriosis (DE; Table 1 and Figure 1C ) was significantly higher (4-fold, p<0.05) than that in the eutopic secretory endometrium. However, no difference was found in EG-VEGF and PKR1 expression between the proliferative and secretory eutopic endometria from patients with endometriosis ( Figure 1A and B). When the expression of the three genes in endometrial biopsies of the same menstrual phase was compared, no difference was found between the normal and the endometriosis groups. The rAFS scores of the endometriosis patients ranges from 1 to 85 with a median value of 4.
Analysis of the relationship between rAFS scores of the endometriosis patients and the mRNA expression of EG-VEGF, PKR1 and PKR2 had a coefficient of correlation 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 
Expression of EG-VEGF, PKR1 and PKR2 in the Paired Eutopic and Ectopic Endometriotic Samples
We further analyzed the expression of VEGF and EG-VEGF mRNA in another sixteen paired human endometriotic samples (Figure 2A 
EG-VEGF Protein Expression in Ectopic Endometriotic Tissues
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DISCUSSION
The expression of EG-VEGF in human endometrium was up-regulated in the secretory phase of the menstrual cycle ( Figure 1A ), consistent with a steroid regulatory mechanism of EG-VEGF production. Higher expression of EG-VEGF was also found in the gonadotropin-stimulated cycle when compared with the natural cycle of patients undergoing assisted reproduction treatment (30) . The hormonal regulation of EG-VEGF expression by progesterone has also been demonstrated using cultured endometrial tissues (31) . Furthermore, our recent study demonstrated that estrogen and/or progesterone stimulate EG-VEGF expression in the human primary endometrial stromal and glandular epithelial cells (30) .
We detected a higher PKR1 and PKR2 mRNA expression in eutopic endometrial samples from normal women (NE) in the proliferative phase ( Figure 1B and C) than in the secretory phase suggesting that the receptors for EG-VEGF (PKR1 and PKR2) may be mainly regulated by estrogen. The differential expression pattern of PKR2, but not PKR1, was also found in the proliferative and secretory eutopic endometria from patients with endometriosis (DE). However, no significant temporal variation of PKR1 and PKR2 mRNA expression was found between the human proliferative and secretory endometria in another study (31) . The reasons for this discrepancy remain unknown. It could be due to the inclusion of the full-thickness of the endometrium with basal endometrial-myometrial region expressing low level of PKR2 in the previous study, whereas only the superficial endometrial layer was analyzed in the present study.
It was interesting to note that the level of EG-VEGF was low whilst that of the transcripts of EG-VEGF receptors (PKR1 and PKR2) was up-regulated in the proliferative endometrium when compared to the secretory endometrium in normal samples. The reason for the dissonance in the expression between EG-VEGF and its receptors was not clear. It was possible that EG-VEGF/PK1 could act on another receptor yet to be defined in the secretory endometrium. In line with this, endometrium expresses another ligand of PKR1 and PKR2, PK2 with level that does not vary significantly in the menstrual cycle (31) . PK2 has a long form spliced variant, PK2L, which is co-expressed with PK2 in many tissues (36) . PK2L produces a peptide, PK2 that can selectively activate PKR1 (36) . The abundance of PK2L in endometrium at different phases of the menstrual cycle is not known. Its determination would be useful to verify the existence of the second possibility.
PKR1 and PKR2 share 87% homology in amino acid sequences and have almost identical transmembrane domain sequence (37) , suggesting that they may have similar activation mechanism (26). However, it was reported that EG-VEGF induces phosphorylation of p44/42 MAPK in the PKR1 transfected cells but not in the PKR2 transfected cells (18) . In mouse, PKR2 is essential for the maturation of the reproductive system as its deficiency is associated with atrophy of the reproductive tract including gonads and endometrium, which has been linked to the lack of gonadotropin-releasing hormone neurons in the hypothalamus (38) . Yet, no abnormality in the reproductive tract of PKR1 knockout mice was found (38, 39) .
When endometrial tissues in the same menstrual phase were compared, there was no significant difference in the mRNA expression of EG-VEGF and its receptors between the normal endometrium and eutopic endometrium from women with endometriosis, indicating that eutopic EG-VEGF expression was not associated with the occurrence of endometriosis. This observation was supported by the present results showing no correlation between the severity of endometriosis (ASRM endometriosis scores) and the mRNA expression of EG-VEGF, PKR1 and PKR2 in the eutopic endometrium.
Human ovary abundantly expresses EG-VEGF and PKR2 but not PKR1 (14, 18) . In order to avoid contamination of endometriotic tissues by neighboring ovarian tissue, we used laser captured micro-dissection to isolate endometriotic tissues. The purity of the laser micro-dissected samples was demonstrated by the very low or undetectable level of PKR2, which is known to be produced abundantly in the ovary.
The micro-dissected ectopic endometriotic tissues used in this study contained both epithelial and stromal cells. They produced EG-VEGF but not its receptors, suggesting paracrine actions of the EG-VEGF most probably act on the neighboring ovarian cells which express PKR2. Consistent with this possibility is the observation that over-expression of EG-VEGF in the rat ovary resulted in excessive angiogenesis and cysts formation (13) . Thus, the increase in EG-VEGF expression in ectopic endometrium when compared with that in the eutopic endometrium is likely to be an event secondary to the initiation of ovarian endometriosis. The expression of EG-VEGF is also associated with polycystic ovary syndrome (16) . The aetiology of EG-VEGF over-expression in ovarian endometriotic cyst warrants further investigation.
Angiogenesis is important in the establishment and growth of endometriosis.
In the ovary, the angiogenic response induced by EG-VEGF is indistinguishable from that by VEGF (14) . However, the expression of ovarian EG-VEGF and VEGF is temporally and spatially complementary to each other (16) , suggesting that the two growth factors have distinct roles and targets in ovarian functions. This may explain why up-regulated levels of EG-VEGF could induce pathophysiological changes in endometriosis even in the presence of other potent angiogenic factors like VEGF.
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